Want to see ENTX full AI Analyst Report?
Top Page
Entera Bio
(NASDAQ:ENTX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$3.50
▲(0.86% Upside)
Action:Reiterated
Date:08/18/26
The score is held back primarily by weak financial performance (no meaningful revenue and significant ongoing cash burn). Offsetting this are constructive technical conditions (price above major moving averages with positive MACD) and positive corporate developments, particularly substantial financing support and progress toward Phase 3 execution. Valuation contributes little given negative earnings and no dividend data.
Positive Factors
Strong funding runway
The sizable financing supports EB613 Phase 3 execution, advances EB612 and other pipeline programs, and reduces near-term dependence on additional capital while the company works toward regulatory milestones.
Negative Factors
No meaningful commercial revenue
Entera remains a clinical-stage business without an approved commercial product, so revenue visibility is limited and future value depends heavily on successful development, regulatory approval and eventual partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong funding runway
The sizable financing supports EB613 Phase 3 execution, advances EB612 and other pipeline programs, and reduces near-term dependence on additional capital while the company works toward regulatory milestones.
Read all positive factors
Entera Bio (ENTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$526.72M
Dividend YieldN/A
Average Volume (3M)123.78K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue Growth-100.00%
EPS Growth-36.92%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding173,834,270
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside159.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$54.58M
Entera Bio Business Overview & Revenue Model
Company Description
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary exp...
How the Company Makes Money
Entera Bio’s ability to generate revenue is primarily tied to (1) collaboration and licensing arrangements and (2) other research-related income, rather than product sales, because it is a clinical-stage company and, to the extent publicly availab...
Entera Bio Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 42.00K | 181.00K | 0.00 | 134.00K | 571.00K |
| Gross Profit | -15.00K | 0.00 | 9.00K | -56.00K | -31.00K | 198.00K |
| EBITDA | -14.26M | -11.41M | -9.48M | -8.80M | -12.87M | -12.16M |
| Net Income | -17.03M | -11.44M | -9.54M | -8.89M | -13.07M | -12.19M |
Balance Sheet | ||||||
| Total Assets | 19.48M | 15.99M | 9.39M | 11.77M | 13.13M | 25.99M |
| Cash, Cash Equivalents and Short-Term Investments | 11.31M | 7.11M | 8.66M | 11.02M | 12.31M | 24.89M |
| Total Debt | 425.00K | 490.00K | 272.00K | 390.00K | 91.00K | 302.00K |
| Total Liabilities | 12.21M | 2.89M | 1.31M | 1.38M | 1.37M | 3.42M |
| Stockholders Equity | 7.27M | 13.10M | 8.08M | 10.39M | 11.75M | 22.57M |
Cash Flow | ||||||
| Free Cash Flow | -11.40M | -7.48M | -6.82M | -7.33M | -12.55M | -9.08M |
| Operating Cash Flow | -11.32M | -7.37M | -6.82M | -7.31M | -12.50M | -9.06M |
| Investing Cash Flow | -75.31K | -107.00K | -3.00K | -17.00K | -102.00K | -17.00K |
| Financing Cash Flow | 11.28M | 13.71M | 4.48M | 6.04M | 13.00K | 25.38M |
Entera Bio Technical Analysis
Positive
3.47
Price Trends
2.40
Positive
1.80
Positive
1.74
Positive
Market Momentum
0.22
Positive
54.91
Neutral
39.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Positive. The current price of 3.47 is above the 20-day moving average (MA) of 3.02, above the 50-day MA of 2.40, and above the 200-day MA of 1.74, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 39.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTX.
Entera Bio Risk Analysis
Entera Bio disclosed 2 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Entera Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $526.72M | -8.74 | -147.19% | ― | -100.00% | -36.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $153.70M | -4.78 | 168.68% | ― | ― | 67.07% | |
47 Neutral | $68.73M | -0.74 | -53.22% | ― | ― | 55.84% | |
46 Neutral | $151.55M | -9.33 | -41.15% | ― | -100.00% | 64.23% | |
42 Neutral | $52.97M | -0.87 | -95.59% | ― | ― | 21.92% |
* Healthcare Sector Average
ENTX
Entera Bio
3.03
1.05
53.03%
ATYR
aTyr Pharma
0.54
-5.11
-90.44%
NRXP
NRX Pharmaceuticals
3.55
0.95
36.54%
EQ
Equillium
2.39
0.67
38.95%
PLRX
Pliant Therapeutics
1.11
-0.57
-33.73%
Entera Bio Corporate Events
Business Operations and StrategyExecutive/Board Changes
Entera Bio appoints new chief medical officer
Positive
Aug 18, 2026
On August 18, 2026, Entera Bio announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer, marking a key addition to its senior leadership as the company moves toward late-stage development. Camisasca, a physician and cl...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Entera Bio Strengthens Finances to Advance Oral Peptide Pipeline
Positive
Aug 7, 2026
Entera Bio reported its second-quarter 2026 results and outlined significant clinical and financing milestones as it advances its oral peptide pipeline. The U.S. FDA aligned in June 2026 on a single 12‑month, 750-patient Phase 3 registration...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Entera Bio Raises $275M in Strategic Private Placement
Positive
Jul 28, 2026
On July 26, 2026, Entera Bio entered into a securities purchase agreement with institutional and accredited investors for a $275 million private placement of 134,803,910 ordinary shares and pre-funded warrants at $2.04 per share, which closed on J...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Entera Bio Expands Share Authorization and Equity Plans
Positive
Jul 17, 2026
At its 2026 Annual Meeting of Shareholders held on July 14, 2026, Entera Bio’s investors approved an amendment to the company’s Articles of Association, increasing authorized ordinary shares from 140,010,000 to 350,000,000. The move, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.